CPT® Code 90393

1. Indications

The vaccinia immune globulin is indicated for use in specific situations where individuals may be at risk of complications from the vaccinia virus. The following conditions warrant the administration of this immunizing agent:

• Post-exposure Prophylaxis - Administered to individuals who have been exposed to the vaccinia virus, particularly those who may experience severe reactions due to their health status or vaccination history.
• Severe Reactions to Vaccinia - Used in patients who have developed severe complications from the smallpox vaccine, such as progressive vaccinia or eczema vaccinatum.
• Immunocompromised Individuals - Recommended for individuals with weakened immune systems who are at higher risk for adverse effects from the vaccinia virus.

2. Procedure

The administration of vaccinia immune globulin involves several key procedural steps to ensure safety and efficacy:

• Step 1: Patient Assessment - Prior to administration, a thorough assessment of the patient's medical history and current health status is conducted to determine the appropriateness of vaccinia immune globulin. This includes evaluating any previous reactions to the smallpox vaccine and identifying any contraindications.
• Step 2: Preparation of the Product - The vaccinia immune globulin is prepared for intramuscular injection. This involves ensuring that the product is stored correctly and is at the appropriate temperature for administration. The vial is inspected for any particulate matter or discoloration before use.
• Step 3: Administration - The immune globulin is administered via intramuscular injection, typically into the deltoid muscle. The injection site is cleaned with an antiseptic solution to minimize the risk of infection. The healthcare provider must follow proper injection techniques to ensure the safety and comfort of the patient.
• Step 4: Monitoring - After administration, the patient is monitored for any immediate adverse reactions or side effects. This observation period is crucial to ensure that any potential allergic reactions or complications are promptly addressed.

3. Post-Procedure

Following the administration of vaccinia immune globulin, patients are advised on post-procedure care and monitoring. They should be informed about potential side effects, which may include mild soreness at the injection site, fever, or fatigue. Patients are encouraged to report any unusual symptoms or reactions to their healthcare provider. Additionally, it is important to follow up with the patient to assess the effectiveness of the treatment and to provide any necessary supportive care. Documentation of the administration, including the lot number of the immune globulin and the injection site, should be completed for compliance and tracking purposes.